The Cambridge Probiotic/Antibiotic Trial 1

Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: A double-blind, placebo-controlled pilot study

SUMMARY

This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.​
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.​
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group

Aim

This randomised, double blind, placebo-controlled study investigated the effect of Lab4 probiotic supplementation on the gut microbiota composition and prevention of pathogenic microorganisms overgrowth in response to antibiotic therapy.

Method

Results

1. Total numbers of facultative anaerobes:
– significantly increased in the patients on antibiotics and placebo at the end of the antibiotic treatment (*P<0.05) and remained increased post antibiotic therapy (*P<0.05) (Group 1).
– significantly increased in the patients on antibiotics and placebo at the end of the antibiotic treatment (*P<0.05), but the numbers decreased significantly after introducing Lab4 probiotic supplementation post antibiotic (*P<0.05, Group 2).
– remained stable in the patients on antibiotics and Lab4 probiotics throughout the study period (Group 3).

 

2. Lab4 probiotic supplementation reduced the overgrowth population of coliforms, enterococci and staphylococci in the re-growth microbiota following antibiotic therapy.

Conclusion

The supplementation of Lab4 probiotics alongside antibiotic therapy has been shown to reduce the overgrowth of undesirable and potentially harmful bacteria both during and following antibiotic therapy.

Reference

Madden JAJ et al 2005. Effects of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: A double-blind, placebo-controlled pilot study. Int Immunopharmacology 5:1091-1097​
Scroll to Top